Jingui Silver Industry: It is planned to invest 19.4 million yuan in the upgrading and reconstruction project of the advanced treatment system of acidic wastewater
Jingui Silver announced that according to the national environmental protection policy, in order to further improve the acid wastewater treatment system, improve the company's safety and environmental protection level, reduce the amount of hazardous waste generated, and reduce the cost of hazardous waste disposal. The company plans to invest in the construction of an advanced acid wastewater treatment system upgrade project. The total investment of the project is expected to be 19.4 million yuan.
Dafeng Industry: Won the bid for the Orange Island Beach Park Project
Dafeng Industrial announced that the company recently received the "Notice of Winning the Bid", confirming that the company won the bid for the Orange Island Beach Park project of Yuelu Mountain Cultural Tourism Company, with a tentative investment of 100 million yuan (the final estimate is subject to the actual calculation of the project plan).
China Resources Shuanghe: The company's drugs have been newly entered into the National Medical Insurance Catalog
China Resources Shuanghe announced that the company's product lacosamide oral solution was included in the "National Medical Insurance Catalog" through bidding, and the exclusive product octafluoropropane lipid microsphere injection was included in the "National Medical Insurance Catalog" through medical insurance negotiations.
Junshi Biosciences: Tuoyi's new indications and Mindewei are included in the new version of the National Medical Insurance Catalog].
Junshi Biosciences announced that the company's two products, toripalimab injection (trade name: Tuoyi) and deuterium hydrobromide tablets (trade name: Mindewei), have passed the national medical insurance negotiation and have been successfully included in the scope of Class B of the national medical insurance catalog. Among them, Tuoyi has added 3 new indications, and all 6 indications that have been approved for marketing in China have been included in the National Medical Insurance Catalog, which is the only anti-PD-1 monoclonal antibody drug for ** melanoma in the National Medical Insurance CatalogFor the first time, Mindwei's indication for adult patients with mild to moderate COVID-19 infection was included in the official National Medical Insurance Catalogue.
Kangyuan Pharmaceutical: Some of the company's drugs are included in the "National Medical Insurance Catalog".
Kangyuan Pharmaceutical announced that the company's exclusive varieties of cold and dampness granules and Linggui Shugan granules were included in the "National Medical Insurance Catalogue" for the first time through negotiationsThe company's exclusive variety ginkgo diterpene lactone meglumine injection was adjusted from the negotiated drug part of the "National Medical Insurance Catalog" during the agreement period to the Chinese patent medicine part, that is, it was included in the regular catalog management;In the National Medical Insurance Catalogue, the scope of medical insurance payment for part of the company's exclusive variety of Retoning Injection has been adjusted from "limited to severe patients in secondary and above medical institutions" to "limited to secondary and above medical institutions".